{"pmid":32406985,"title":"Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.","text":["Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.","Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS-CoV-2 induced inflammatory syndrome by utilization of the interleukin-6 receptor antagonist (IL-6Ra) tocilizumab.","Transpl Infect Dis","Allam, Sridhar R","Dao, Ann","Madhrira, Machaiah M","Antiporta, Philip B","Nair, Ranjit R","Guiteau, Jacfranz J","Reyad, Ashraf I","32406985"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS-CoV-2 induced inflammatory syndrome by utilization of the interleukin-6 receptor antagonist (IL-6Ra) tocilizumab."],"journal":"Transpl Infect Dis","authors":["Allam, Sridhar R","Dao, Ann","Madhrira, Machaiah M","Antiporta, Philip B","Nair, Ranjit R","Guiteau, Jacfranz J","Reyad, Ashraf I"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406985","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/tid.13326","e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666802845273292801,"score":9.490897,"similar":[{"pmid":32422376,"title":"Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","text":["Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.","Int J Infect Dis","Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania","32422376"],"abstract":["We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection."],"journal":"Int J Infect Dis","authors":["Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422376","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.050","keywords":["anakinra","cytokine-release syndrome","interleukin-1 receptor antagonist","novel coronavirus disease 2019 (covid-19)","remdesivir"],"topics":["Case Report"],"weight":1,"_version_":1667159284442464256,"score":159.03749},{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":144.67758},{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490384941057,"score":131.17302},{"pmid":32476261,"title":"Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.","text":["Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.","There is emerging data depicting the clinical presentation of COVID-19 in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some infected with SARS-CoV-2, beginning with a flu-like illness followed by an intense inflammatory response characterized by elevated c-reactive protein (CRP), interleukin 6 (IL-6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL-6. Tocilizumab is an IL-6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T-cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS-CoV-2-related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS-CoV-2-related ARDS that received tocilizumab with favorable short-term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab's clinical utility in this population.","Am J Transplant","Morillas, Jose A","Marco Canosa, Francisco","Srinivas, Pavithra","Asadi, Tannaz","Calabrese, Casandra","Rajendram, Prabalini","Budev, Marie","Poggio, Emilio D","Narayanan Menon, K V","Gastman, Brian","Koval, Christine","32476261"],"abstract":["There is emerging data depicting the clinical presentation of COVID-19 in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some infected with SARS-CoV-2, beginning with a flu-like illness followed by an intense inflammatory response characterized by elevated c-reactive protein (CRP), interleukin 6 (IL-6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL-6. Tocilizumab is an IL-6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T-cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS-CoV-2-related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS-CoV-2-related ARDS that received tocilizumab with favorable short-term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab's clinical utility in this population."],"journal":"Am J Transplant","authors":["Morillas, Jose A","Marco Canosa, Francisco","Srinivas, Pavithra","Asadi, Tannaz","Calabrese, Casandra","Rajendram, Prabalini","Budev, Marie","Poggio, Emilio D","Narayanan Menon, K V","Gastman, Brian","Koval, Christine"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476261","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16080","topics":["Treatment"],"weight":1,"_version_":1668437835052482560,"score":130.12605},{"pmid":32500922,"title":"Failed antibody response in a renal transplant recipient with SARS-CoV-2 infected.","text":["Failed antibody response in a renal transplant recipient with SARS-CoV-2 infected.","In late December 2019, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has been identified as a novel pathogen causing Coronavirus Disease 2019 (COVID-19) in Wuhan, China, subsequently spread to the rest of China and has been demonstrating a rapid global spread. Nucleic acid testing (NAT, tested by real-time polymerase chain reaction) of SARS-CoV-2 virus in oropharyngeal/nasal swab samples has been described to be extremely sensitive for the diagnose of SARS-CoV-2 infection, but false-negative results have been reported. Recent months, researches demonstrated the importance of IgM/IgG antibody detecting due to the unsatisfied positive rate of NAT, and the increasement IgM/IgG antibody was considered as a confirmed criteria of diagnosis in the official guides of the diagnosis and treatment of COVID-19 in China (7(th) Edition) .","Transpl Infect Dis","Xia, Zhiping","Liu, Xiaojun","Hu, Xiaoyan","Zhong, Zibiao","Wang, Yanfeng","Peng, Guizhu","Ye, Qifa","32500922"],"abstract":["In late December 2019, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has been identified as a novel pathogen causing Coronavirus Disease 2019 (COVID-19) in Wuhan, China, subsequently spread to the rest of China and has been demonstrating a rapid global spread. Nucleic acid testing (NAT, tested by real-time polymerase chain reaction) of SARS-CoV-2 virus in oropharyngeal/nasal swab samples has been described to be extremely sensitive for the diagnose of SARS-CoV-2 infection, but false-negative results have been reported. Recent months, researches demonstrated the importance of IgM/IgG antibody detecting due to the unsatisfied positive rate of NAT, and the increasement IgM/IgG antibody was considered as a confirmed criteria of diagnosis in the official guides of the diagnosis and treatment of COVID-19 in China (7(th) Edition) ."],"journal":"Transpl Infect Dis","authors":["Xia, Zhiping","Liu, Xiaojun","Hu, Xiaoyan","Zhong, Zibiao","Wang, Yanfeng","Peng, Guizhu","Ye, Qifa"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500922","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13349","locations":["Wuhan","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668890966283517952,"score":123.378586}]}